Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study
Open Access
- 1 October 2020
- journal article
- editorial
- Published by Elsevier BV in Cell
- Vol. 183 (1), 4-10
- https://doi.org/10.1016/j.cell.2020.09.005
Abstract
No abstract availableFunding Information
- Royal Marsden Cancer Charity (RMCC32)
- Royal Marsden NHS Foundation Trust
This publication has 17 references indexed in Scilit:
- Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital SystemCancer Discovery, 2020
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020
- Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung CancersCancer Discovery, 2020
- Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)Annals Of Oncology, 2020
- Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19Annals Of Oncology, 2020
- Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 OutbreakCancer Discovery, 2020
- Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatmentClinical and Translational Radiation Oncology, 2020
- Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, ChinaAnnals Of Oncology, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020
- PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activityJournal for ImmunoTherapy of Cancer, 2019